Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2019

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms LAVOLTA II
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 25 Feb 2019 Results of post-hoc analysis assessing stability of eosinophil levels from four studies (LUTE, VERSE, LAVOLTA I and LAVOLTA II) presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 23 May 2018 Results of a post-hoc analysis from NCT01867125 and NCT01868061 studies presented at the 114th International Conference of the American Thoracic Society.
    • 08 Mar 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top